Catalyst Pharmaceuticals (CPRX) Total Non-Current Liabilities (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 16 years of Total Non-Current Liabilities data on file, last reported at $134.6 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 17.76% year-over-year to $134.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.6 million (up 17.76% YoY) and the FY2025 annual result came in at $149.5 million, up 21.09% from the prior year.
• Total Non-Current Liabilities eased to $134.6 million in Q1 2026, from $149.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $149.5 million in Q4 2025 to a low of $48.3 million in Q3 2022.
• A 5-year average of $94.7 million and a median of $95.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 97.52% — and 2026, when it gained 17.76%.
• Tracing CPRX's Total Non-Current Liabilities over 5 years: stood at $61.1 million in 2022, then climbed by 29.61% to $79.3 million in 2023, then jumped by 55.79% to $123.5 million in 2024, then advanced by 21.09% to $149.5 million in 2025, then slipped by 9.95% to $134.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $134.6 million (Q1 2026), $149.5 million (Q4 2025), and $131.2 million (Q3 2025), per Business Quant data.